PRGO

#4423
Perrigo Company plc Ordinary Shares
0.1 1 USD
-3.57%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
0.11
0.11
년간 변동
0.11
22.01
일일 변동
-3.57%
월간 변동
-99.02%
6달 변화
-99.17%
년간 변동율
-99.49%
이전 종가
0.1 1
Open
0.1 1
저가
0.1 1
High
0.1 1
양
1 167
전체 차트 열기 Full chart

Financials

개요 성명 통계 배당금
4분기 연간
  • Market Capitalization 15.3 M
  • Employee 8 100
  • Founded N/A
  • CEO Murray S. Kessler
  • Website www.perrigo.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry 전문의약품 및 제네릭 의약품 제조업체
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-1.35
주가매출액비율
0.45
주당 배당금
1.16
배당수익률 %
8.33

Perrigo Company plc Ordinary Shares

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.

뉴스